Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands.
Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1054-60. doi: 10.1016/j.ijrobp.2009.03.045. Epub 2010 Jan 25.
Health-related quality of life (HRQOL) after prostate brachytherapy has been extensively described in published reports but hardly any long-term data are available. The aim of the present study was to prospectively assess long-term HRQOL 6 years after (125)I prostate brachytherapy.
A total of 127 patients treated with (125)I brachytherapy for early-stage prostate cancer between December 2000 and June 2003 completed a HRQOL questionnaire at five time-points: before treatment and 1 month, 6 months, 1 year, and 6 years after treatment. The questionnaire included the RAND-36 generic health survey, the cancer-specific European Organization for Research and Treatment of Cancer core questionnaire (EORTCQLQ-C30), and the tumor-specific EORTC prostate cancer module (EORTC-PR25). A change in a score of >/=10 points was considered clinically relevant.
Overall, the HRQOL at 6 years after (125)I prostate brachytherapy did not significantly differ from baseline. Although a statistically significant deterioration in HRQOL at 6 years was seen for urinary symptoms, bowel symptoms, pain, physical functioning, and sexual activity (p <.01), most changes were not clinically relevant. A statistically significant improvement at 6 years was seen for mental health, emotional functioning, and insomnia (p <.01). The only clinically relevant changes were seen for emotional functioning and sexual activity.
This is the first study presenting prospective HRQOL data up to 6 years after (125)I prostate brachytherapy. HRQOL scores returned to approximately baseline values at 1 year and remained stable up to 6 years after treatment. (125)I prostate brachytherapy did not adversely affect patients' long-term HRQOL.
前列腺近距离放射治疗后的健康相关生活质量（HRQOL）已在已发表的报告中进行了广泛描述，但几乎没有长期数据可用。本研究的目的是前瞻性评估前列腺近距离放射治疗后 6 年的长期 HRQOL。
2000 年 12 月至 2003 年 6 月期间，共有 127 例接受（125）I 前列腺近距离放射治疗的早期前列腺癌患者在五个时间点完成了 HRQOL 问卷：治疗前、治疗后 1 个月、6 个月、1 年和 6 年。问卷包括 RAND-36 通用健康调查、欧洲癌症研究与治疗组织核心问卷（EORTCQLQ-C30）的癌症特异性部分以及肿瘤特异性欧洲癌症研究与治疗组织前列腺癌模块（EORTC-PR25）。评分变化> = 10 分被认为具有临床意义。
总体而言，前列腺近距离放射治疗后 6 年的 HRQOL 与基线相比没有显著差异。尽管在 6 年后，尿症状、肠症状、疼痛、身体功能和性活动的 HRQOL 出现了统计学上的显著恶化（p <.01），但大多数变化没有临床意义。在 6 年后，心理健康、情感功能和失眠得到了统计学上的显著改善（p <.01）。只有心理健康、情感功能和失眠的变化具有临床意义。
这是第一项前瞻性报告（125）I 前列腺近距离放射治疗后长达 6 年的 HRQOL 数据的研究。HRQOL 评分在 1 年后恢复到接近基线值，并在治疗后 6 年内保持稳定。（125）I 前列腺近距离放射治疗不会对患者的长期 HRQOL 产生不利影响。
